盐酸哈尔酚 | 40580-83-4

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 中文名称: 盐酸哈尔酚
• 英文名称: HARMOL HYDROCHLORIDE
• 英文别名: harmalol HCl；harmol；1-methyl-9H-β-carbolin-7-ol; hydrochloride；1-Methyl-9H-β-carbolin-7-ol; Hydrochlorid；1-methyl-β-carbolin-7-ol hydrochloride
• CAS: 40580-83-4
• 化学式: C₁₂H₁₀N₂O*ClH
• 分子量: 234.685
• InChiKey: IBINNLDPMFWTTI-UHFFFAOYSA-N

物化性质

• 熔点：
  265-267 °C(Solv: water (7732-18-5); methanol (67-56-1); ethanol (64-17-5))

计算性质

• 辛醇/水分配系数(LogP)：
  3.15
• 重原子数：
  16.0
• 可旋转键数：
  0.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  48.91
• 氢给体数：
  2.0
• 氢受体数：
  2.0

安全信息

• 海关编码：
  2933990090
• 安全说明：
  S24/25

反应信息

• 作为反应物：
  描述：

  盐酸哈尔酚 、 2,6-蒽二酚 在 phosphate buffer pH 6 作用下， 以 水 为溶剂， 生成
  参考文献：
  名称：

  Spectroscopic study of molecular associations between FMN and β-carbolines

  摘要：

  The spectrophotometric and thermodynamic properties of molecular complexes of flavin mononucleotide (FMN) (riboflavin 5'-phosphate) with some beta-carboline derivatives have been investigated in aqueous solution. The molecular associations have been examined by means of electronic absorption spectra, since in each a new charge-transfer band has been located, and also the variation of the fluorescence emission of FMN on the solutions has been observed. The formation constants for the molecular complexes were determined from absorption data using the Foster-Hammick-Wardley method. The quenching phenomenon observed in FMN fluorescence is related to the concentration of the beta-carboline derivatives, allowing the calculation of the quenching constants for FMN-beta-carboline complexes. Thermodynamic parameters have been determined from the values of association constants for the molecular complexes at various temperatures. The influence of substituents in the beta-carboline molecule on the stability of the complexes formed was also investigated.

  DOI：

  10.1016/0584-8539(93)80248-9

文献信息

• SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR
  申请人：Diamond Marc

  公开号：US20080293766A1

  公开（公告）日：2008-11-27

  The present invention provides a method of inhibiting an androgen receptor by administering a compound of Formula I: or a compound of Formula II: wherein R 1 , R 2 , R 3 and R 8 are each independently hydrogen or C 1-6 alkyl. R 4 is absent or is hydrogen, C 1-6 alkyl or C 1-6 alkyl-OH. R 5 is hydrogen, C 1-6 alkyl or —NR 6 R 7 . R 6 and R 7 are each independently hydrogen or C 1-6 alkyl, or are combined with the nitrogen to which they are attached to form a heterocycloalkyl having from 5 to 7 ring members. L is a linker of C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene or C 3-6 cycloalkylene. The compounds of Formula I include the salts, hydrates and prodrugs thereof. Each R 9 is H, C 1-6 alkyl, —OH or —O—C 1-6 alkyl. The compounds of Formulas I and II include the salts, hydrates and prodrugs thereof. By administering the compound of Formula I or II, the method inhibits the androgen receptor.

  本发明提供了通过给予式I的化合物或式II的化合物来抑制雄激素受体的方法：其中R1、R2、R3和R8分别独立地为氢或C1-6烷基。R4不存在或为氢、C1-6烷基或C1-6烷基-OH。R5为氢、C1-6烷基或-NR6R7。R6和R7分别独立地为氢或C1-6烷基，或与它们连接的氮原子结合形成具有5至7个环成员的杂环烷基。L为C1-6烷基、C2-6烯基、C2-6炔基或C3-6环烷基的连接剂。式I的化合物包括其盐、水合物和前药。每个R9为H、C1-6烷基、-OH或-O-C1-6烷基。式I和II的化合物包括其盐、水合物和前药。通过给予式I或II的化合物，该方法抑制雄激素受体。
• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Small molecule toll-like receptor (TLR) antagonists
  申请人：Lipford B. Grayson

  公开号：US20050119273A1

  公开（公告）日：2005-06-02

  The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.

  本发明提供了用于调节通过Toll样受体信号传导的方法和组合物。该方法涉及使用含有至少两个环的核心结构的小分子与表达TLR的细胞接触。其中某些化合物是4-主氨基喹啉。许多化合物和方法特别适用于抑制涉及至少一个TLR9、TLR8、TLR7和TLR3的免疫刺激。该方法可用于治疗自身免疫、炎症、过敏、哮喘、移植排斥、移植物抗宿主病、感染、败血症、癌症和免疫缺陷。
• THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT
  申请人：Ions Pharmaceutical S.À R.L.

  公开号：EP3275465A1

  公开（公告）日：2018-01-31

  Human therapeutic treatment compositions comprise the combination of at least one harmine component, and at least one isovanillin component, wherein the components of the composition are different. The compositions are effective for the treatment of human conditions, especially human cancers.

  人类治疗组合物由至少一种禾本科成分和至少一种异香兰素成分组合而成，其中组合物的成分各不相同。这些组合物可有效治疗人类疾病，尤其是人类癌症。
• Methods and compositions for treating infection
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US10004701B2

  公开（公告）日：2018-06-26

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。